CoChat

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

Open access
Ferrari, Roberto, Aguiar, Carlos, Alegria, Eduardo, Bonadonna, Riccardo C., Cosentino, Francesco, Elisaf, Moses, Farnier, Michel, Ferrières, Jean, Filardi, Pasquale Perrone, Hancu, Nicolae, Kayikcioglu, Meral, Mello e Silva, Alberto, Millan, Jesus, Reiner, Željko, Tokgozoglu, Lale, Valensi, Paul, Viigimaa, Margus, Vrablik, Michal, Zambon, Alberto, Zamorano, José Luis, Catapano, Alberico L. · 2016 · European Heart Journal Supplements
Cited by 97

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to managing cardiovascular risk in clinical practice, including residual cardiovascular risk associated with lipid abnormalities, such as atherogenic dyslipidaemia (AD). A simplified definition of AD was proposed to enhance understanding of this condition, its prevalence, and its impact on cardiovascular risk. Atherogenic dyslipidaemia can be defined by high fasting triglyceride levels (≥2.3 mmol/L) and low high-density lipoprotein cholesterol (HDL-c) levels (≤1.0 and ≤1.3 mmol/L in men and women, respectively) in statin-treated patients at high cardiovascular risk. The use of a single marker for the diagnosis and treatment of AD, such as non-HDL-c, was advocated. Interventions including lifestyle optimization and low-density lipoprotein (LDL)-lowering therapy with statins (±ezetimibe) are implemented by all experts. Treatment of residual AD can be performed with the addition of fenofibrate, since it can improve the complete lipoprotein profile and reduce the risk of cardiovascular events in patients with AD. Specific clinical scenarios in which fenofibrate may be prescribed are discussed, and include patients with very high triglycerides (≥5.6 mmol/L), patients who are intolerant or resistant to statins, and patients with AD and at high cardiovascular risk. The fenofibrate-statin combination was considered by the experts to benefit from a favourable benefit-risk profile. Cardiovascular experts adopt a multifaceted approach to the prevention of atherosclerotic cardiovascular disease, with lifestyle optimization, LDL-lowering therapy, and treatment of AD with fenofibrate routinely used to help reduce a patient's overall cardiovascular risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/suw009

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 97

Metadata

Authors
Ferrari, R., Aguiar, C., Alegria, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hancu, N., Kayikcioglu, M., Mello e Silva, A., Millan, J., Reiner, Ž., Tokgozoglu, L., Valensi, P., Viigimaa, M., Vrablik, M., Zambon, A., Zamorano, J. L., & Catapano, A. L.
Venue
European Heart Journal Supplements
Published
2016-04-12
Volume
18
Issue
suppl_C
Pages
C2-C12
ISSN
  • 1520-765X (ISSN-L)
  • 1554-2815
OpenAlex
W2337193712
Cited by
97
References
23
FWCI
9.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. https://app.cochat.ai/papers/10.1093/eurheartj/suw009
The paper
Ferrari, R., Aguiar, C., Alegria, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hancu, N., Kayikcioglu, M., Mello e Silva, A., Millan, J., Reiner, Ž., Tokgozoglu, L., Valensi, P., Viigimaa, M., Vrablik, M., Zambon, A., . . . Catapano, A. L. (2016). Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. European Heart Journal Supplements. https://doi.org/10.1093/eurheartj/suw009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.